Topical Gene Therapy Heals Blistering Skin Disease Lesions
A novel topical gene therapy healed most lesions among patients with dystrophic epidermolysis bullosa, a rare genetic blistering skin disease, the GEM-3 trial showed. Topical administration of beremagene geperpavec (B-VEC) led to complete healing of 67% of treated wounds as compared with 22% of those exposed to placebo at 6 months (P=0.002), reported M. Peter […]